Evanthia Bernitsas, MD

Evanthia Bernitsas, MD


(313) 745-4275

Evanthia Bernitsas, MD

Narrative Bio

Evanthia Triantafylou-Bernitsas, MD joined the Department of Neurology at Wayne State University in 2011. She has completed a neurology residency at Case Western Reserve University and Neuroimmunology Fellowships at the University of Michigan and Baylor College of Medicine. She is the Director of the Multiple Sclerosis Center at Wayne State School of Medicine and an Associate Professor of Neurology.

Her clinical research focuses on aggressive forms of MS, new immunomodulatory therapies and symptomatic interventions. Dr. Bernitsas directs a very active clinical research program and she is the PI on numerous clinical and investigator-initiated trials.

Her laboratory research interests include novel neuroimaging and optical coherence tomography that lead to a better understanding of the disease, pathophysiology and imaging of MS fatigue and the use of biomarkers in neuroprotection and remyelination. Currently, she serves as the Editor-in Chief in the Neuroimaging section of the “Brain Sciences” Journal. She has published extensively and served in several committees and advisory boards.

Office Address

8D University Health Center, 4201 St Antoine

1) Sudden hearing loss as an early detector of multiple sclerosis: a systematic review. Di Stadio A, Dipietro L, Ralli M, Meneghello F, Minni A, Greco A, Stabile MR, Bernitsas E. Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4611-4624.

2) Multiple Sclerosis Fatigue: A Longitudinal Structural MRI and Diffusion Tensor Imaging Study. Yarraguntla K, Seraji-Bozorgzad N, Lichtman-Mikol S, Razmjou S, Bao F, Sriwastava S, Santiago-Martinez C, Khan O, Bernitsas E.
J Neuroimaging. 2018 Nov;28(6):650-655.

3) Expiratory and phonation times as measures of disease severity in patients with Multiple Sclerosis. A case-control study.
Nordio S, Bernitsas E, Meneghello F, Palmer K, Stabile MR, Dipietro L, Di Stadio A.
Mult Scler Relat Disord. 2018 Jul;23:27-32.

4) From Postural Orthostatic Tachycardia Syndrome to Radiologically Isolated Syndrome.
Tripathi R, Bernitsas E.
Case Rep Neurol Med. 2018 Feb 25;2018:2956387.

5) Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study.
Di Stadio A, Bernitsas E, Restivo DA, Alfonsi E, Marchese-Ragona R.
J Voice. 2018 Apr 9. pii: S0892-1997(17)30590-8.

6) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Lancet. 2018 Mar 31;391(10127):1263-1273.

7) Pathophysiology and Imaging Diagnosis of Demyelinating Disorders. Bernitsas E., Brain Sci. 2018 Mar 14;8(3).

8) Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.
Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O. PLoS One. 2018 Jan 8;13(1).

9) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.
Lancet Neurol. 2017 Dec;16(12):976-986.

10) Structural and Neuronal Integrity Measures of Fatigue Severity in Multiple Sclerosis.
Bernitsas E, Yarraguntla K, Bao F, Sood R, Santiago-Martinez C, Govindan R, Khan O, Seraji-Bozorgzad N.
Brain Sci. 2017 Aug 12;7(8).

11) Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis. Bernitsas E, Khan O, Razmjou S, Tselis A, Bao F, Caon C, Millis S, Seraji-Bozorgzad N. PLoS One. 2017 Jul 20;12(7):e0181431.

12) Fulminant tumefactive multiple sclerosis in pregnancy. Pakneshan S, Bernitsas E.
BMJ Case Rep. 2017 Jun 13;2017.

13) Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis.
Seraji-Bozorgzad N, Khan O, Cree BAC, Bao F, Caon C, Zak I, Razmjou S, Tselis A, Millis S, BernitsasE.
J Neuroimaging. 2017 Sep;27(5):476-480.

14) Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. N Engl J Med. 2017 Jan 19;376(3):209-220.

15) Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.
N Engl J Med. 2017 Jan 19;376(3):221-234.

16) Bilateral cisternal abducens nerve involvement with ophthalmoplegic migraine.
Tripathi R, Tselis A, Bernitsas E.
Cephalalgia. 2017 Oct;37(12):1211-1212.

17) Characterizing retinal structure injury in African-Americans with multiple sclerosis.
Seraji-Bozorgzad N, Reed S, Bao F, Santiago C, Tselis A, Bernitsas E, Caon C, Frohman E, Bhatti MT, Cree BA, Khan O. Mult Scler Relat Disord. 2016 May;7:16-20.

18) Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes.
Bernitsas E, Bao F, Seraji-Bozorgzad N, Chorostecki J, Santiago C, Tselis A, Caon C, Zak I, Millis S, Khan O. Mult Scler Relat Disord. 2015 Jan;4(1):47-51.



Aristotelian Medical School, Thessaloniki, Greece, MD, 1990

Position Title

Associate Professor of Neurology,  Director of the Multiple Sclerosis Center


Mercy Health Partners, Toledo, OH, 2004-2005


Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, 2005-2008


• Walter Reed Army Medical Center, NIH/USUHS, Bethesda, MD, 1991-1993
• University of Michigan, Ann Arbor, MI, 2000-2004
• Maxine Mesinger Comprehensive MS Center, Baylor College of Medicine, Houston, TX, 2008-2009

Prior Appointments

University of Michigan, Assistant Professor, 2009-2011


MS fatigue, MS and epilepsy, Neuroimaging and OCT

← Return to listing